KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Operations (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Cash from Operations data on record, last reported at 8469000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 30.51% year-over-year to 8469000.0; the TTM value through Dec 2025 reached 52432000.0, down 46.63%, while the annual FY2025 figure was 52432000.0, 46.63% down from the prior year.
  • Cash from Operations reached 8469000.0 in Q4 2025 per AQST's latest filing, up from 12649000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 8816000.0 in Q1 2023 and bottomed at 23400000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 6868450.0, with a median of 7910500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: skyrocketed 204.4% in 2022, then tumbled 406.18% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 8061000.0 in 2021, then surged by 204.4% to 8416000.0 in 2022, then tumbled by 158.72% to 4942000.0 in 2023, then plummeted by 31.3% to 6489000.0 in 2024, then crashed by 30.51% to 8469000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 8469000.0 in Q4 2025, 12649000.0 in Q3 2025, and 7914000.0 in Q2 2025.